SAGE THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.7 USD | -2.58% |
|
-5.19% | -46.01% |
Presenter SpeechTazeen Ahmad (Analysts)Good afternoon. Thanks for taking time to sit it in, in...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Sage Therapeutics, Inc. is a biopharmaceutical company. The Company has developed the two FDA-approved treatments indicated for postpartum depression and is advancing a robust pipeline to target unmet needs in brain health. The Company is targeting diseases and disorders of the brain across its clinical development and earlier stage pipeline. Its product ZURZUVAE is for the treatment of postpartum depression (PPD) in adults. ZURZUVAE is a neuroactive steroid that is a positive allosteric modulator of GABA receptors, targeting both synaptic and extra synaptic GABA receptors. Its product ZULRESSO (brexanolone) CIV injection is for the treatment of PPD in individuals 15 years old and older. It is also developing a portfolio of other novel compounds that target GABA receptors, including SAGE-324, which is a novel GABAA receptor positive allosteric modulator intended for chronic oral dosing. Its second area of focus for development is novel compounds that target the NMDA receptor.
Calendar
2024-06-10
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
HOLD
Number of Analysts
21
Last Close Price
12.01
USD
Average target price
22.24
USD
Spread / Average Target
+85.14%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -46.01% | 723M | |
| +9.42% | 114B | |
| +11.84% | 104B | |
| -14.15% | 22.41B | |
| -1.05% | 22.28B | |
| -5.29% | 19.07B | |
| -38.29% | 18B | |
| -4.16% | 17.89B | |
| +7.99% | 14.28B | |
| +36.24% | 12.55B |
- Stock Market
- Equities
- SAGE Stock
- News Sage Therapeutics, Inc.
- Transcript : Sage Therapeutics, Inc. Presents at Bank of America Securities 2023 Healthcare Conference, May-10-2023 02
